SCHEMBL31269342

SCHEMBL31269342

CC1(Oc2ncnc3c2nc(-c2ccc(OCCCOCC(=O)O)cc2Cl)n3Cc2cccc(Cl)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 3/20 0.38
▸ PPARD Q03181 3/20 0.38
▸ TLR7 Q9NYK1 1/20 0.35
▸ CNR1 P21554 3/20 0.35
▸ PIK3CD O00329 2/20 0.34
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ FFAR1 O14842 2/20 0.33
▸ MAOB P27338 1/20 0.33
▸ PLA2G2A P14555 4/20 0.32
▸ S1PR1 P21453 1/20 0.32
▸ S1PR3 Q99500 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ HTR6 P50406 1/20 0.32
▸ PLA2G1B P04054 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268983 0.99 PPARG (0.37) PPARGPPARDTLR7CNR1PIK3CD
SCHEMBL30983422 0.96 PPARG (0.35) PPARGPPARDTLR7CNR1PIK3CD
SCHEMBL31268778 0.96 PPARG (0.35) PPARGPPARDTLR7CNR1PIK3CD
SCHEMBL31269376 0.94 PPARG (0.34) PPARGPPARDTLR7CNR1PIK3CD
SCHEMBL30983523 0.92 PLA2G2A (0.38) PPARGPPARDTLR7CNR1PIK3CD
SCHEMBL30983451 0.92 PLA2G2A (0.38) PPARGPPARDTLR7CNR1PIK3CD
SCHEMBL31269035 0.92 CNR1 (0.36) PPARGPPARDTLR7CNR1PIK3CD
SCHEMBL31269373 0.91 PLA2G2A (0.37) PPARGPPARDTLR7CNR1PIK3CD
SCHEMBL31268872 0.91 PLA2G2A (0.37) PPARGPPARDTLR7CNR1PIK3CD
SCHEMBL31268992 0.90 CNR1 (0.35) PPARGPPARDTLR7CNR1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback